Galmed Pharmaceuticals (NASDAQ:GLMD) Shares Pass Above Fifty Day Moving Average – Time to Sell?

Shares of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) passed above its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $0.62 and traded as high as $0.6250. Galmed Pharmaceuticals shares last traded at $0.6040, with a volume of 24,519 shares.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Galmed Pharmaceuticals in a research note on Tuesday, April 21st. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has an average rating of “Sell”.

Galmed Pharmaceuticals Price Performance

The company has a market capitalization of $3.31 million, a PE ratio of -0.49 and a beta of 0.62. The company has a 50 day moving average of $0.62 and a two-hundred day moving average of $0.77.

Institutional Investors Weigh In On Galmed Pharmaceuticals

A hedge fund recently bought a new stake in Galmed Pharmaceuticals stock. Two Sigma Investments LP bought a new position in Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 21,200 shares of the biopharmaceutical company’s stock, valued at approximately $29,000. Two Sigma Investments LP owned approximately 1.28% of Galmed Pharmaceuticals at the end of the most recent quarter. Institutional investors and hedge funds own 76.14% of the company’s stock.

About Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for metabolic and liver diseases. The company’s principal program centers on Aramchol, a synthetic fatty acid-bile acid conjugate designed to reduce liver fat accumulation and fibrosis in patients with nonalcoholic steatohepatitis (NASH). Galmed conducts translational research to validate its mechanism of action and advance its drug candidates through regulatory trials.

In addition to Aramchol, Galmed maintains a pipeline of complementary small-molecule compounds aimed at modulating lipid metabolism and inflammatory pathways implicated in chronic liver disorders.